If you have been reading about ESI-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical form for research-grade material |
| Solubility | Soluble in water | Aqueous buffer also used |
| Typical storage | -20 degrees Celsius or below | Desiccated and protected from light |
| Primary analytical method | RP-HPLC with UV detection | Purity expressed as relative peak area |
| Identity confirmation | ESI-MS or LC-MS | Compared with calculated 711.85 Da |
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Contaminants of emerging concern (CEC) is a term used by water quality professionals to describe pollutants that have been detected in environmental monitoring samples, that may cause ecological or human health impacts, and typically are not regulated under current environmental laws. Sources of these pollutants include agriculture, urban runoff and ordinary household products (such as soaps and disinfectants) and pharmaceuticals that are disposed to sewage treatment plants and subsequently discharged to surface waters. CEC include different substances like pharmaceuticals, personal care products, industrial byproducts, and agricultural chemicals. These substances often bypass regular detection and treatment processes, leading to their unintended persistence in the environment. The complexity of CEC arises not only from their different chemical nature but also from the complex ways they interact with ecosystems and human health. As such, they are the focus of increasing examination by researchers, policymakers, and public health officials who want to understand their long-term effects and develop effective interventions. Global initiatives, like those from the World Health Organization (WHO) and the United States Environmental Protection Agency (US EPA), emphasize the need to create international standards and effective environmental policies to address the challenges posed by CEC.
Colistimethate sodium may be used to treat Pseudomonas aeruginosa infections in patients with cystic fibrosis, and it has come into recent use for treating multidrug-resistant Acinetobacter infection, although resistant forms have been reported. Colistimethate sodium has also been given intrathecally and intraventricularly in Acinetobacter baumannii and Pseudomonas aeruginosa meningitis and ventriculitis Some studies have indicated that colistin may be useful for treating infections caused by carbapenem-resistant isolates of Acinetobacter baumannii. Colistin sulfate may be used to treat intestinal infections, or to suppress colonic flora. Colistin sulfate is also used in topical creams, powders, and otic solutions. Colistin A (polymyxin E1) and colistin B (polymyxin E2) can be purified individually to research and study their effects and potencies as separate compounds.
Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency. Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist. It is a growth hormone secretagogue receptor (ghrelin receptor) agonist, causing release of growth hormone from the pituitary gland. Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate. Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France. This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound. As of January 2014, it was in Phase III clinical trials. The phase III trial for growth hormone deficiency is expected to be complete in December 2016. As of December 2017, it was FDA-approved as a method to diagnose growth hormone deficiency. Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers. In November 2018 Novo Nordisk would acquire the rights to Macrilen, at a cost of $145 million.
With Muir gone, the remaining members continued as a four-piece, releasing Starless and Bible Black in March 1974. Earning a positive Rolling Stone review, most of the album was recorded live during the band's late 1973 tour, with the recordings carefully edited and overdubbed to sound like studio recordings, while "The Great Deceiver", "Lament" and the second half of "The Night Watch" were recorded entirely in the studio. The album reached No. 28 in the UK and No. 64 in the US. Following the album's release, the band began to divide once more, this time over performance. Musically, Fripp found himself positioned between Bruford and Wetton, who played with such force and increasing volume that Fripp once compared them to "a flying brick wall", and Cross, whose amplified acoustic violin was consistently drowned out by the rhythm section, leading him to concentrate more on keyboards. An increasingly frustrated Cross began to withdraw both musically and personally, with the result being that he was voted out of the group following the band's 1974 tour.
Sources: en.wikipedia.org
The National Association of Newspapers spoke about the case in a statement:The ANJ follows with concern and expresses its repudiation of attempts at intimidation against O Estado de S.Paulo and its Politics editor, Andreza Matais, after the newspaper disclosed the access of the wife of a leader of organized crime in Amazonas to offices of the Ministry of Justice. The use of intimidation methods against outlets and journalists is not consistent with democratic values and demonstrates blatant disrespect for freedom of the press. It also shows a practice characteristic of autocratic regimes of, with the support of political leaders, pro-government sites and influencers, attempting to divert attention from uncomfortable reporting by attacking those who investigate and disclose it. The ANJ expects such intimidation methods, especially against women journalists already employed in the recent past, to cease immediately, in the name of respect for freedom of the press and the free exercise of journalism and communication outlets.
The MNHN has been called "the Louvre of the Natural Sciences". Its largest and best-known gallery is the Grand Gallery of Evolution, located at the end of the central alley facing the formal garden. It replaced an earlier Neoclassical gallery built next to the same by Buffon, opened in 1785, and demolished in 1935. It was proposed in 1872 and begun in 1877 by the architect Louis-Jules André, a teacher at the influential École des Beaux-Arts in Paris. It is a prominent example of Beaux Arts Architecture. It was opened in 1889 for the Paris Universal Exposition of 1889, which also presented the Eiffel Tower. It was never fully completed in its original design; it never received the neoclassical entrance planned for the side of the building away from the garden, facing Rue Geoffroy-Saint-Hilaire. The facade of the building was designed specifically as a backdrop for the garden. The facade facing the garden is divided into eleven traverses. Ten are decorated with sculpted medallions honouring prominent French scientists associated with the MNHN. The central traverse has a larger marble statue of a woman seated holding a book, in a pose similar to that of statue of Buffon facing the building. The statues are the work of Eugene Guillaume, a pupil of the sculptor Pradier. While the building exterior was neo-classical, the iron framework of the interior was extremely modern for the 19th century, like that of the Gare d'Orsay railroad station of the same period.
During the development of Half-Life 2, Newell spent months developing Steam, a digital distribution service for games. By 2011, Steam controlled between 50% and 70% of the market for downloaded PC games and generated most of Valve's revenue. At a technology conference in Seattle that year, Newell argued that software piracy was best addressed by offering a superior option rather than pursuing anti-piracy technology. He cited Steam's success in Russia, where piracy is rife, as an example. Following the difficult development of Half-Life 2, Newell said he became "obsessed" with improving Valve's work-life balance.In 2007, Newell expressed his displeasure over developing for game consoles, saying that developing processes for Sony's PlayStation 3 was a "waste of everybody's time". On stage at Sony's keynote at E3 2010, he acknowledged his criticism but discussed the open nature of the PlayStation 3 and announced a port of Portal 2, remarking that with Steamworks support it would be the best version for any console. Newell also criticized the Xbox Live service, referring to it as a "train wreck", and Windows 8, calling it a threat to the open nature of PC gaming. At the 2013 LinuxCon, Newell said the Linux operating system and open source development were "the future of gaming". He accused the proprietary systems of companies such as Microsoft and Apple of stifling innovation through slow certification processes.
Sources: en.wikipedia.org
== Theranos == In May 2015, Diamandis performed a deep investigation into claims of health technology company Theranos and concluded in a report that "most of the company's claims are exaggerated." This insight from Diamandis triggered John Carreyrou to further investigate the claims that had been made by Theranos. At the time, Theranos was widely considered a reliable and functional analysis company.
Based on evidence from the geologic record, life most likely emerged on Earth between 4.32 and 3.48 Gya. In 2017, the earliest physical evidence of life was reported to consist of microbialites in the Nuvvuagittuq Greenstone Belt of Northern Quebec, in banded iron formation rocks at least 3.77 and possibly as old as 4.32 Gya. The micro-organisms could have lived within hydrothermal vent precipitates, soon after the 4.4 Gya formation of oceans during the Hadean. The microbes resemble modern hydrothermal vent bacteria, supporting the view that abiogenesis began in such an environment. Later research disputed this interpretation of the data, stating that the observations may be better explained by abiotic processes in silica-rich waters, "chemical gardens," circulating hydrothermal fluids, or volcanic ejecta. Biogenic graphite has been found in 3.7 Gya metasedimentary rocks from southwestern Greenland and in microbial mat fossils from 3.49 Gya cherts in the Pilbara region of Western Australia. Evidence of early life in rocks from Akilia Island, near the Isua supracrustal belt in southwestern Greenland, dating to 3.7 Gya, have shown biogenic carbon isotopes. In other parts of the Isua supracrustal belt, graphite inclusions trapped within garnet crystals are connected to the other elements of life: oxygen, nitrogen, and possibly phosphorus in the form of phosphate, providing further evidence for life 3.7 Gya.
Loose connective tissue is characterized by few fibers and cells, and a relatively large amount of ground substance. Dense connective tissue has a smaller amount of ground substance compared to the fibrous material. The meaning of the term has evolved over time.
Sources: en.wikipedia.org
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.
Once dissolved, the peptide is exposed to hydrolysis, oxidation, and aggregation pathways that are slowed in the dry state. Freeze-thaw cycling and warm storage accelerate these losses. Keeping the lyophilized powder cold and dry is the usual way to limit degradation.
No single pharmacopeial monograph covers ipamorelin, so suppliers apply their own specifications. Certificates of analysis therefore differ in the tests performed and the limits set. Independent laboratory verification is often needed to compare materials from different sources.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.